The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC

Trial Profile

The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as the supplies of study drug were halted by Gilead Sciences Ltd.
    • 18 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top